熱門資訊> 正文
Pelthos Therapeutics完成与Channel Therapeutics的合并,完成5010万美元私募发行,并为2025年7月ZELSUavi上市做准备
2025-07-02 19:14
- The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025
- Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement
- Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。